Figure 1
Figure 2
Comparison between clinical and pathological T stage (n = 537; completeness = 99_6%)
| cT1 (N = 240) N (%) | cT2 (N = 193) N (%) | cT3 (N = 96) N (%) | cT4 (N = 8) N (%) | |
|---|---|---|---|---|
| pT1 | 187 (78%) | 24 (13%) | 10 (10%) | 2 (25%) |
| pT2 | 46 (19%) | 158 (82%) | 41 (43%) | 3 (37%) |
| pT3 | 5 (2%) | 9 (4%) | 42 (44%) | 2 (25%) |
| pT4 | 2 (1%) | 2 (1%) | 3 (3%) | 1 (13%) |
Comparison between clinical and pathological N stage (n = 534; completeness = 99_1%)
| cN0 (N = 388) N (%) | cN1 (N = 102) N (%) | cN2 (N = 44) N (%) | |
|---|---|---|---|
| pN0 | 324 (84%) | 49 (48%) | 13 (30%) |
| pN1 | 42 (11%) | 34 (33%) | 5 (11%) |
| pN2 | 22 (6%) | 19 (19%) | 26 (59%) |
Demographic, clinicopathological and treatment characteristics of study population
| Characteristic | N (%) |
|---|---|
| No. of patients | 539 |
| Age in years: median (range) | 64 (39–83) |
| < 65 years | 271 (50.3) |
| ≥ 65 years | 268 (49.7) |
| Gender | |
| Male | 315 (58.4) |
| Female | 224 (41.6) |
| Smoking status (n = 537; completeness = 99.6 %) | |
| Current | 257 (47.8) |
| Former | 212 (39.5) |
| Never | 68 (12.7) |
| Histology | |
| Adenocarcinoma | 341 (63.3) |
| Squamous-cell carcinoma | 195 (36.2) |
| NSCLC other rare types | 3 (0.6) |
| EGFRa status in non-squamous NSCLC | |
| (n = 334; completeness = 99.7%) | |
| Positive | 41 (12.3) |
| Negative | 292 (87.7) |
| ALKb status in non-squamous NSCLC | |
| (n = 334; completeness = 39.2%) | |
| Positive | 7 (5.3) |
| Negative | 124 (94.7) |
| Clinical TNM stagec | |
| I | 309 (57.3) |
| II | 145 (26.9) |
| IIIA | 85 (15.8) |
| Clinical T stage | |
| T1 | 242 (44.9) |
| T2 | 193 (35.8) |
| T3 | 96 (17.8) |
| T4 | 8 (1.5) |
| Clinical N stage | |
| N0 | 393 (72.9) |
| N1 | 102 (18.9) |
| N2 | 44 (8.2) |
| Pathological TNM stagec (n = 532; completeness = 98.7%) | |
| I | 296 (55.6) |
| II | 150 (28.2) |
| III | 86 (16.2) |
| Pathological T stage (n = 537; completeness = 99.6%) | |
| T1 | 223 (41.5) |
| T2 | 248 (46.2) |
| T3 | 58 (10.8) |
| T4 | 8 (1.5) |
| Pathological N stage (n = 534; completeness = 99.1% | |
| N0 | 386 (72.3) |
| N1 | 81 (15.2) |
| N2 | 67 (12.5) |
| Surgery type | |
| Lobectomy | 459 (85.2) |
| Bilobectomy | 31 (5.8) |
| Pneumonectomy | 49 (9.1) |
| Adjuvant treatment | |
| Platinum-based chemotherapy | 146 (27.1) |
| Postoperative radiotherapy | 36 (6.7) |
Univariate analyses of overall survival
| Factor | p-value | HR (95% CI) |
|---|---|---|
| Age | ||
| < 65 | 1 | |
| ≥ 65 | 0.002 | 1.59 (1.18 – 2.15) |
| Gender | ||
| Male | 1 | |
| Female | 0.001 | 0.59 (0.43 – 0.81) |
| Smoking status | ||
| never | 1 | |
| current or former | 0.115 | 1.50 (0.91 – 2.47) |
| Histology | ||
| adenocarcinoma or NOS | 1 | |
| squamous cell carcinoma | 0.111 | 1.28 (0.95 – 1.73) |
| EGFR statusa (positive vs negative) | ||
| negative | 1 | |
| positive | 0.111 | 0.56 (0.27 – 1.14) |
| Clinical TNM stage | 0.027* | |
| I | 1 | |
| II | 0.034 | 1.44 (1.03 – 2.02) |
| IIIA | 0.025 | 1.57 (1.06 – 2.34) |
| Clinical T stage | 0.001* | |
| T1 | 1 | |
| T2 | 0.882 | 0.97 (0.69 – 1.38) |
| T3 or T4 | 0.001 | 1.86 (1.29 – 2.68) |
| Clinical N stage | 0.317* | |
| N0 | 1 | |
| N1 | 0.958 | 0.99 (0.67 – 1.46) |
| N2 | 0.137 | 1.44 (0.89 – 2.34) |
| Pathological TNM stage | 0.003* | |
| I | 1 | |
| II | 0.030 | 1.46 (1.04 – 2.06) |
| IIIA | 0.001 | 1.90 (1.29 – 2.79) |
| Pathological T stage | 0.007* | |
| T1 | 1 | |
| T2 | 0.019 | 1.49 (1.07 – 2.07) |
| T3 or T4 | 0.004 | 1.92 (1.23 – 2.98) |
| Pathological N stage | 0.002* | |
| N0 | 1 | |
| N1 | 0.054 | 1.48 (0.99 – 2.20) |
| N2 | 0.001 | 1.93 (1.29 – 2.87) |
Multivariate analyses of overall survival (separate for clinical and for pathological stage)
| Cox regression model with clinical stage | p-value | HR (95% CI) |
|---|---|---|
| Age | ||
| < 65 | 1 | |
| ≥ 65 | 0.003 | 1.58 (1.17 – 2.14) |
| Gender | ||
| Male | 1 | |
| Female | 0.006 | 0.63 (0.46 – 0.88) |
| Clinical TNM stage | 0.092* | |
| I | 1 | |
| II | 0.078 | 1.36 (0.97 – 1.91) |
| IIIA | 0.068 | 1.46 (0.97 – 2.18) |
| Cox regression model with pathological stage | p-value | HR (95% CI) |
| Age | ||
| < 65 | 1 | |
| ≥ 65 | 0.001 | 1.68 (1.24 – 2.28) |
| Gender | ||
| Male | 1 | |
| Female | 0.004 | 0.62 (0.45 – 0.86) |
| Pathological TNM stage | 0.003* | |
| I | 1 | |
| II | 0.076 | 1.37 (0.97 – 1.93) |
| IIIA | 0.001 | 1.95 (1.32 – 2.88) |
Comparison between clinical (c) and pathological (p) TNM staging2A_ Comparison between clinical and pathological TNM stage (n = 532; completeness = 98_7%)
| c Stage I (N = 303) N (%) | c Stage II (N = 144) N (%) | c Stage IIIA (N = 85) N (%) | |
|---|---|---|---|
| p Stage I | 246 (81%) | 38 (26%) | 12 (14%) |
| p Stage II | 40 (13%) | 79 (55%) | 31 (36%) |
| p Stage IIIA | 17 (6%) | 27 (19%) | 42 (49%) |